Your browser version may not work well with NCBI's Web applications. More information here...
1: J Biol Chem. 2000 Nov 24;275(47):36927-33.Click here to read Links

X-ray crystal structure of a small antagonist peptide bound to interleukin-1 receptor type 1.

Vigers GP, Dripps DJ, Edwards CK 3rd, Brandhuber BJ.

Department of Inflammation Research, Amgen, Incorporated, Boulder, Colorado 80301, USA. gvigers@arraybiopharma.com

Interleukin (IL-1)alpha and IL-1beta are important mediators of inflammation. The binding of IL-1 to interleukin-1 receptor (IL-1R) type 1 is the initial step in IL-1 signal transduction and therefore is a tempting target for anti-inflammatory therapeutics. To advance our understanding of IL-1R1 binding interactions, we have determined the structure of the extracellular domains of IL-1R1 bound to a 21-amino acid IL-1 antagonist peptide at 3.0-A resolution. The antagonist peptide binds to the domain 1/2 junction of the receptor, which is a conserved binding site for IL-1beta and IL-1 receptor antagonist (IL-1ra). This co-crystal structure also reveals that considerable flexibility is present in IL-1R1 because the carboxyl-terminal domain of the receptor is rotated almost 170 degrees relative to the first two domains of the receptor compared with the previously solved IL-1R1.ligand structures. The structure shows an unexpected binding mode for the peptide and may contribute to the design of smaller IL-1R antagonists.

PMID: 10903327 [PubMed - indexed for MEDLINE]

Structures reported by this article

Patient Drug Information

  • Anakinra (Kineret® )

    Anakinra is used, alone or in combination with other medications, to reduce the pain and swelling associated with rheumatoid arthritis. Anakinra is in a class of medications called interleukin antagonists. It works by bl...

  • Abatacept (Orencia, Humira, Amevive, ...)

    How do targeted immune modulators compare in treating rheumatoid arthritis?

  • Source: AHFS Consumer Medication Information